EP Patent

EP4374851B1 — Ophthalmic composition for treatment of dry eye disease

Assigned to Novaliq GmbH · Expires 2026-04-15 · 0y expired

What this patent protects

Patent listed against Sandimmune.

Drugs covered by this patent

Sandimmune (cyclosporine) · Novartis AG (originally Sandoz)

Patent Metadata

Patent number: EP4374851B1
Jurisdiction: EP
Classification: —
Expires: 2026-04-15
Drug substance claim: No
Drug product claim: No
Assignee: Novaliq GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.